



US009493744B2

(12) **United States Patent**  
**Shiratori et al.**

(10) **Patent No.:** **US 9,493,744 B2**  
(45) **Date of Patent:** **Nov. 15, 2016**

(54) **METHODS FOR VIRAL INACTIVATION AND OTHER ADVENTITIOUS AGENTS**(71) Applicant: **Genentech, Inc.**, South San Francisco, CA (US)(72) Inventors: **Masaru Ken Shiratori**, Burlingame, CA (US); **Robert David Kiss**, San Mateo, CA (US); **Hardayal Prashad**, Richmond, CA (US); **Raquel Iverson**, Pacifica, CA (US); **Justin Bourret**, San Francisco, CA (US); **Michael Kim**, San Francisco, CA (US); **Salim Charaniya**, Encinitas, CA (US)(73) Assignee: **GENENTECH, INC.**, South San Francisco, CA (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 346 days.

(21) Appl. No.: **13/844,051**(22) Filed: **Mar. 15, 2013**(65) **Prior Publication Data**

US 2013/0344570 A1 Dec. 26, 2013

**Related U.S. Application Data**

(60) Provisional application No. 61/662,349, filed on Jun. 20, 2012.

(51) **Int. Cl.**

<b>C12Q 1/70</b>	(2006.01)
<b>C12N 7/00</b>	(2006.01)
<b>C12N 1/36</b>	(2006.01)

(52) **U.S. Cl.**

CPC .	<b>C12N 7/00</b> (2013.01);	<b>C12N 1/36</b> (2013.01);
	<b>C12N 2750/14061</b> (2013.01)	

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

## U.S. PATENT DOCUMENTS

4,153,509 A *	5/1979	Schwartz .....	435/129
RE30,985 E	6/1982	Cartaya .....	
4,339,216 A	7/1982	Bell .....	
4,560,655 A	12/1985	Baker .....	
4,657,866 A	4/1987	Kumar .....	
4,767,704 A	8/1988	Cleveland et al.	
4,816,567 A	3/1989	Cabilly et al.	
4,927,762 A	5/1990	Darfler .....	
5,091,178 A	2/1992	Hellstrom et al.	
5,122,469 A	6/1992	Mather et al.	
6,180,401 B1	1/2001	Chen et al.	
2003/0180766 A1 *	9/2003	Farnet et al. .....	435/6

## FOREIGN PATENT DOCUMENTS

EP	0 117 058 B1	8/1984
EP	0 117 060 A2	8/1984
EP	0 117 060 A3	8/1984

EP	0 307 247 A2	3/1989
EP	0 307 247 A3	3/1989
EP	0 307 247 B1	3/1989
EP	0 404 097 A2	12/1990
EP	0 404 097 A3	12/1990
EP	0 404 097 B1	12/1990
WO	WO-87/00195 A1	1/1987
WO	WO-90/03430 A1	4/1990
WO	WO-91/08291 A2	6/1991
WO	WO-91/08291 A3	6/1991
WO	WO-93/11161 A1	6/1993
WO	WO 2013/192395 A1	12/2013

## OTHER PUBLICATIONS

Awad. "Fouling of Heat Transfer Surfaces," Chapter 20 in *Heat Transfer: Theoretical Analysis, Experimental Investigations and Industrial Systems*, pp. 505-542, (2011).

Barnes et al. "Methods for growth of cultured cells in serum-free medium," *Anal. Biochem.* 102:255-270, (1980).

Cao et al. "Identification and Root Cause Analysis of Cell Culture Media Precipitates in the Viral Deactivation Treatment with High-Temperature/Short-time Method," *Journal of Pharmaceutical Science and Technology* 67(1):63-73, (Jan. 2013).

Chothia et al. "Canonical structures for the hypervariable regions of immunoglobulins," *J. Mol. Biol.* 196:901-917, (1987).

Clackson et al. "Making antibody fragments using phage display libraries," *Nature* 352:624-628, (Aug. 15, 1991).

DePalma. "Quantifying Cell Culture Media Quality," *Genetic Engineering & Biotechnology News* 31(2):28-32, (Jan. 15, 2011).

Gething et al. "Cell-surface expression of influenza haemagglutinin from a cloned DNA copy of the RNA gene," *Nature* 293:620-625, (Oct. 22, 1981).

Graham et al., "Characteristics of a human cell line transformed by DNA from Human Adenovirus type 5," *J. Gen. Virol.* 36:59-72, (1977).

Graham et al., "A new technique for the assay of infectivity of human adenovirus 5 DNA," *Virology* 52:456-467, (1973).

Ham et al., "Media and growth requirements," *Methods in Enzymology* 58:44-93, (1979).

Hammerling et al., "Research Monographs in Immunology," vol. 3, in *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., pp. 563-587, (1981).

Holliger et al., "Diabodies": Small bivalent and bispecific antibody fragments, *Proc. Natl. Acad. Sci. USA* 90:6444-6448, (Jul. 1993).

International Search Report mailed on Aug. 21, 2013, for PCT Application No. PCT/US2013/046756, filed on Jun. 20, 2013, 3 pages.

Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," *Nature* 321:522-525, (May 1986).

Keown et al., "Methods for introducing DNA into mammalian cells," *Methods in Enzymology* 185:527-537, (1990).

Kiss, R. "Practicing safe cell culture: applied process designs for minimizing virus contamination risk," *PDA J. Pharm. Sci. and Tech.* 65:715-729, (2011).

(Continued)

Primary Examiner — Michelle S Horning

(74) Attorney, Agent, or Firm — Morrison & Foerster LLP

(57) **ABSTRACT**

The invention provides for methods of viral inactivation using high temperature short time (HTST) treatment and adjustment of various parameters such that generation of precipitate and depositions of precipitate are reduced and/or minimized.